risk stratification

Related by string. Risk Stratification * risking . risked . Risks . risks . RISK . Risk . Risking . RISKS : High Risk Warning . Risk Factors section . Key Risk Ranking . heading Risk Factors . Item 1A Risk Factors . Risk Ranking Declines . entitled Risk Factors . Youth Risk Behavior / Stratification . stratifications : Social Stratification . stratification * Rapid Risk Stratification *

Related by context. All words. (Click for frequent words.) 70 stratify patients 65 prognostic 65 prognostic indicators 64 antiplatelet agents 64 acute coronary syndromes 64 prognostic variables 63 FDG PET 63 Framingham Risk Score 62 stratifying patients 62 Prognostic 62 subclinical atherosclerosis 61 prostate cancer CaP 61 PD2i ® 61 predictive biomarkers 61 PROLARIS 61 prognostic markers 61 prognostic marker 61 MTWA testing 61 MTWA 61 adjuvant therapies 61 biomarkers 60 Fractional Flow Reserve 60 antihypertensive agents 60 LV dysfunction 60 PD2i R 60 NSTE ACS 60 MDRD equation 60 biomarker 60 warfarin dosing 60 EGFR mutation status 60 NT proBNP 60 coronary revascularization 60 antithrombotic therapy 60 antithrombotic therapies 60 Risk Stratification 60 Afib 60 lipid lowering therapy 60 pretest probability 60 ICD implantation 59 FDG-PET/CT 59 coronary intervention 59 diagnostic modality 59 COR Analyzer 59 Prostate Px + 59 antiplatelet therapies 59 APPRAISE 59 predictive biomarker 59 D dimer 59 antiplatelet therapy 59 noninvasive diagnostic 59 warfarin therapy 59 multivessel disease 58 prognostic biomarker 58 molecular biomarkers 58 Cardiotoxicity 58 resynchronization therapy 58 Thrombolysis 58 hsCRP 58 SYNTAX trial 58 systolic hypertension 58 interventional therapies 58 multivessel coronary artery 58 clinically localized prostate 58 adjuvant therapy 58 OnDose TM 58 coronary stenting 58 thrombolytic therapy 58 atherothrombotic disease 58 pharmacogenetic 58 pharmacodynamic PD 58 KRAS mutation 58 PSADT 58 QRISK 58 Corus CAD 58 immunochemical fecal occult 58 cardiac computed tomography 58 stratify 58 myocardial viability 58 nomograms 58 coronary angiography 58 oral anticoagulation 58 genetic biomarkers 58 deCODE AF TM 58 urine dipstick 58 carotid artery stenting 58 MSCT 58 Septin9 57 postoperative atrial fibrillation 57 PD2i 57 preoperative staging 57 biomarker identification 57 echocardiographic parameters 57 catheter angiography 57 noninvasive imaging 57 CT angiography 57 coronary CT angiography 57 genomic biomarker 57 PITX2 57 unstable angina UA 57 intravenous thrombolysis 57 investigational therapies 57 Coronary CTA 57 pelvic lymphadenectomy 57 MADIT II 57 cytoreductive nephrectomy 57 ischemic cardiomyopathy 57 platelet reactivity 57 diagnostic prognostic 57 molecular biomarker 57 MADIT 57 Coronary artery calcium 57 stable angina 57 patients undergoing percutaneous 57 contrast echocardiography 57 pharmacologic intervention 57 microalbuminuria 57 PCA3 assay 57 diagnosing coronary artery 57 electron beam computed tomography 57 chronic myocardial ischemia 57 refractory angina 57 STRIDE PD 57 nonpharmacologic 57 acute coronary syndrome 57 reperfusion therapy 57 statin therapy 57 antithrombotic 57 cirrhotic patients 57 cardiac resynchronisation therapy 57 eTag assays 57 EBUS FNA 57 ST elevation myocardial 57 endocrine therapies 57 Coronary Artery Bypass Graft 57 lymphadenectomy 57 oncologic outcomes 56 eptifibatide 56 coronary interventions 56 stress echocardiography 56 neoadjuvant chemotherapy 56 revascularisation 56 PICSO ® 56 Acute Coronary Syndrome 56 chronic thromboembolic pulmonary 56 Trandolapril 56 periprocedural MI 56 postoperative radiotherapy 56 postoperative AF 56 Lp PLA2 56 chemosensitivity 56 repeat revascularization 56 echocardiographic 56 prospectively defined 56 curative resection 56 Candesartan 56 surrogate endpoint 56 lipid lowering drugs 56 colonoscopic 56 nonischemic 56 angiographically 56 hyperacute 56 coronary artery calcium 56 neoadjuvant treatment 56 Octreolin 56 viral kinetics 56 glycoprotein IIb IIIa inhibitors 56 SCD HeFT 56 mRCC 56 KRAS mutation status 56 lymphatic mapping 56 hepatorenal syndrome 56 ACC AHA SCAI 56 NGAL 56 metastatic renal cell carcinoma 56 dose atorvastatin 56 cCTA 56 prophylactic therapy 56 VTE prophylaxis 56 detecting colorectal cancer 56 thromboprophylaxis 56 angiographic outcomes 56 gefitinib Iressa 56 prognostic biomarkers 56 CYP#C# [001] 56 CT Colonography 56 arterial thrombosis 56 VKORC1 56 TAXUS Express Stent 56 neratinib 56 antithrombotic agents 56 diagnostic biomarker 56 Troponin 56 intravesical therapy 56 endothelin antagonists 56 conventional angiography 56 urine cytology 56 proteomic biomarkers 56 microvolt T wave alternans 56 glycosylated hemoglobin levels 56 #F FDG PET 56 Chronic Heart Failure 56 comorbid conditions 56 ADHF 56 Epigenomics proprietary 56 UA NSTEMI 56 Outpatient Setting 56 ICD therapy 56 skin sterol 56 EUS FNA 56 periprocedural 56 arteriography 56 carotid artery stenting CAS 56 immunohistochemical 56 Accelerated Partial Breast Irradiation 55 angioplasty stenting 55 coronary computed tomography 55 intravascular ultrasonography 55 aldosterone antagonists 55 ischemic complications 55 genomewide 55 antiplatelet medications 55 invasive coronary angiography 55 angiotensin converting enzyme inhibitors 55 SPECT MPI 55 RE LY 55 upper gastrointestinal bleeding 55 Percutaneous Coronary Intervention 55 adjuvant chemotherapy 55 platelet inhibition 55 HER2 expression 55 myocardial ischemia 55 warfarin dosage 55 ACC AHA 55 p# biomarker 55 CT angiograms 55 nephron sparing surgery 55 pharmacogenetic tests 55 Prostate Specific Antigen PSA 55 undergoing coronary angiography 55 aromatase inhibitors AIs 55 lipid lowering agents 55 severe aortic stenosis 55 eGFR 55 tirofiban 55 nonfasting triglyceride levels 55 percutaneous interventions 55 miRview ™ mets 55 DVT PE 55 PITX2 methylation 55 myocardial infarction MI 55 angiography CTA 55 carotid bruit 55 anticoagulation 55 antiplatelet drugs 55 Radical prostatectomy 55 revascularization procedures 55 cerebral oximetry 55 patients undergoing CABG 55 MiCK assay 55 CTAP# Capsules 55 Masimo SpHb 55 thrombotic complications 55 venous thromboembolism VTE prophylaxis 55 HER2 overexpression 55 IMPROVE HF 55 perfusion imaging 55 ACRIN 55 ADVEXIN therapy 55 DNA methylation markers 55 atherothrombosis 55 Angiographic 55 endoscopic ultrasonography 55 Mammostrat 55 revascularization 55 adverse cytogenetics 55 β blockers 55 Nesiritide 55 anticoagulation therapy 55 HERmark 55 electrophysiologic 55 neoadjuvant 55 VADT 55 renal artery stenosis 55 nonlinear algorithm 55 molecular profiling 55 prescribe statins 55 F FDG PET 55 Secondary efficacy endpoints 55 Haptoglobin 55 pertuzumab 55 XIENCE V PROMUS Stent 55 KIF6 carriers 55 dyslipidaemia 55 diabetes mellitus DM 55 obstructive coronary artery 55 peptide BNP 55 deCODE BreastCancer TM 55 ventricular tachyarrhythmia 55 cervical carcinoma 55 pharmacogenetic test 55 Randomized clinical trials 55 coronary stenosis 55 liver transplant recipients 55 antiarrhythmic drug 55 graft patency 55 HER2 positive cancers 55 epigenetic therapies 55 epithelial ovarian cancer 55 GRNCM1 55 electrocardiography ECG 55 EGFR TKIs 55 chemoradiotherapy 55 diabetic kidney 55 acute ischemic stroke 55 BioImage Study 55 T1a 55 postoperative complication 55 carotid stenting 55 recurrent glioblastoma multiforme 55 ACUITY trial 55 prostate carcinoma 55 thrombus aspiration 55 pharmacological approaches 55 FFR measurement 55 GI motility disorders 54 atherosclerotic renal artery stenosis 54 atherosclerosis regression 54 Surgical resection 54 anticoagulant therapy 54 coronary revascularization procedures 54 immunomodulation 54 etiologic 54 microRNA biomarkers 54 chemoprevention 54 pharmacologic stress 54 putative biomarkers 54 thromboembolic disease 54 micrometastasis 54 transient elastography 54 pharmacodynamic biomarkers 54 molecular diagnostic assays 54 prognostically 54 thoracoscopic lobectomy 54 T2DM 54 recursive partitioning 54 nonrandomized 54 carotid stenosis 54 transcranial Doppler ultrasound 54 carotid revascularization 54 occlusive disease 54 prognostic indicator 54 HIV HCV coinfected 54 VerifyNow P#Y# 54 Myocardial Infarction 54 repair TEVAR 54 FFR guided treatment 54 miRview mets 54 endovascular therapy 54 Coronary artery bypass grafting 54 prognostic significance 54 antiangiogenic agents 54 APTIMA HPV 54 Trofex 54 DVT prophylaxis 54 Bucindolol 54 antiangiogenic agent 54 preoperative chemotherapy 54 ST Segment Elevation 54 ß blockers 54 transrectal ultrasound guided 54 stratifying 54 concomitant medications 54 bevacizumab Avastin 54 TroVax ® 54 pharmacologic therapy 54 carotid endarterectomy 54 thyroid nodules 54 surrogate marker 54 aerosolized KL4 surfactant 54 elective PCI 54 NADiA TM 54 potentially modifiable 54 myocardial perfusion 54 biomarker assays 54 riociguat 54 clinically validated 54 lymph node dissection 54 diagnostic 54 coronary CTA 54 tumor subtypes 54 OPCAB 54 miRview ™ squamous 54 subgroup analyzes 54 colorectal adenoma 54 angina myocardial infarction 54 myocardial infarction stroke 54 recurrent DVT 54 lung resection 54 beta blocker therapy 54 peripheral arterial disease 54 epithelial tumors 54 CYT# potent vascular disrupting 54 Adjuvant chemotherapy 54 antiangiogenic therapy 54 molecular abnormalities 54 Xelox 54 PCa 54 D Dimer 54 cerebral perfusion 54 obstructive CAD 54 thromboembolic 54 angiography CCTA 54 NPM1 mutation 54 esophagogastric 54 Subgroup analyzes 54 CT Angiography 54 neoadjuvant therapy 54 HGPIN 54 genetic polymorphisms 54 Lp PLA 2 54 DCE MRI 54 pigmented skin lesions 54 diagnostic workup 54 tumor hypoxia 54 serum biomarkers 54 specific antigen PSA 54 endarterectomy 54 nonalcoholic steatohepatitis NASH 54 hematological parameters 54 chest radiography 54 PROactive study 54 angiotensin receptor blockers ARBs 54 prospective multicentre 54 multicentric 54 cardiovascular morbidity 54 virological response 54 NCCN guidelines 54 pretransplant 54 Coronary angiography 54 serum phosphorous 54 therapeutic regimens 54 perfusion CT 54 HORIZONS AMI trial 54 precursor lesions 54 Val HeFT 54 binary logistic regression 54 Occlusive Disease 54 completely resected 54 Sudden Cardiac Death 54 acetabular fractures 54 microsatellite instability 54 helical CT 54 CHADS 54 MIST II 54 sunitinib malate 53 thetreatment 53 histopathologic 53 renal tumors 53 anti angiogenic agents 53 pathophysiological mechanisms 53 HSCT 53 eplerenone 53 soluble CD# ligand 53 SYNTAX 53 antidiabetic drugs 53 intracerebral haemorrhage 53 multivariate Cox 53 lipoprotein levels 53 prasugrel Effient 53 NMP# 53 CARE HF 53 antihypertensive medications 53 diagnostic assays 53 genomic alterations 53 CHAMPION PCI 53 NATRECOR R 53 PreDx DRS 53 atrial arrhythmias 53 Unstable angina 53 prostate cancer PCa 53 DCVax R 53 MEND CABG II 53 intracoronary 53 pharmacokinetic PK 53 postoperative morbidity 53 Cardiolite ® 53 cytoreductive surgery 53 kidney urologic 53 ATTR CM 53 myocardial revascularization 53 MGd 53 FDG PET imaging 53 radionuclide therapy 53 tumor histology 53 silent myocardial ischemia 53 nodal metastasis 53 quantitative gene expression 53 HPV genotyping 53 immunosuppressive regimens 53 antitumor effect 53 sensitivity specificity 53 HIPEC 53 carotid IMT 53 paclitaxel eluting stents 53 liver metastasis 53 transcranial Doppler 53 kinase inhibition 53 histological subtype 53 postoperative mortality 53 CaPSURE 53 urothelial carcinoma 53 percutaneous intervention 53 immunochemical 53 segment elevation myocardial 53 multislice CT 53 infarction NSTEMI 53 conventional coronary angiography 53 diagnostic biomarkers 53 Xanafide 53 PGxPredict 53 Cystatin C 53 carotid intima media 53 Carotid Revascularization Endarterectomy vs. 53 SSc 53 coinfected patients 53 Sentinel Lymph Node Biopsy 53 adjuvant radiotherapy 53 transcatheter aortic valve implantation 53 percutaneous biopsy 53 NYHA functional class 53 diagnose Alzheimer disease 53 Recurrence Score 53 presymptomatic 53 multicenter trials 53 CHADS2 53 PLAC test 53 surgical revascularization 53 MDRD 53 poor metabolizers 53 delta isoform 53 BrachySil TM 53 troponins 53 Lenalidomide 53 valvular disease 53 computed tomography angiography 53 comorbidity 53 invasive aspergillosis 53 SPECT CT imaging 53 coronary artery disease 53 cytologic 53 differentiated thyroid 53 C Reactive Protein 53 aetiology 53 GAMMAGARD 53 rNAPc2 53 differentiate squamous 53 biochemical recurrence 53 relapsed SCLC 53 galectin 3 53 cediranib 53 debulking surgery 53 hemodynamic variables 53 Tyrima 53 fine needle aspiration 53 sirolimus eluting stents 53 multimodality therapy 53 stereotactic radiotherapy 53 pediatric malignancies 53 levosimendan 53 SPECT imaging 53 lymph node biopsies 53 bronchial hyperresponsiveness 53 thrombo embolic 53 rEEG 53 NSABP B 53 eNO 53 HIF PH inhibitors 53 death reinfarction 53 tumor necrosis 53 NMIBC 53 abnormal cytology 53 perioperative morbidity 53 thrombotic events 53 longitudinal cohort study 53 atherogenic dyslipidemia 53 unresectable tumors 53 lipid abnormalities 53 computed tomography CT angiography 53 adenomatous 53 CABG 53 Enzastaurin 53 multigene expression test 53 alvespimycin 53 Poisson regression 53 ExTRACT TIMI 53 miRview squamous 53 Logistic regression 53 undergoing radical prostatectomy 53 cardioembolic stroke 53 clinico pathological 53 ErbB2 positive 53 antigen PSA 53 VeriStrat 53 thrombophilia 53 spinal metastases 53 IVUS 53 exploratory endpoints 53 assessing T DM1 53 trials RCTs 53 PressureWire 53 International Prognostic Scoring 53 drug eluting stent DES 53 curative therapy 53 CT colonography 53 hematopoietic cancers 53 everolimus eluting stents 53 intracranial stenosis 53 pharmacodynamic endpoints 53 Venous thromboembolism 53 Oncotype 53 TAXUS Liberte Stent 53 renal denervation 53 decompensated heart failure 53 MammaPrint R 53 DNA methylation biomarker 53 central corneal thickness 53 Endoscopic ultrasound 53 resuscitated cardiac arrest 53 Flow cytometry 53 electrocardiography 53 aldosterone antagonist 53 colonography 53 atherosclerotic disease 53 preoperative diagnosis 53 galiximab 53 allogeneic HSCT 53 Doxil ® 53 KRAS status 53 SERCA2a 53 BSGI MBI 53 BRACAnalysis ® 53 PCA3 53 fondaparinux 53 hypertensive patients 53 functional mitral regurgitation 53 medically inoperable 53 genomic biomarkers 53 circulating endothelial cells 52 Acute Coronary Syndromes ACS 52 thrombolysis 52 OncotypeDX 52 T1DM 52 Statin therapy 52 Belldegrun 52 Torisel 52 PET imaging 52 nomogram 52 undergoing coronary artery 52 randomized controlled trials RCTs 52 Acute MI 52 refractory colorectal cancer 52 Uncontrolled hypertension 52 cardiac biomarkers 52 antibiotic prophylaxis 52 squamous cell lung cancer 52 imaging modality 52 antifungal therapy 52 relapsed MM 52 Carotid artery stenting 52 chemoprevention trials 52 dietary modification 52 Squamous 52 tissue perfusion 52 multiplex PCR 52 MEND CABG 52 univariate 52 Cloretazine 52 mixed hyperlipidemia 52 adenomatous polyps 52 nonfatal myocardial infarction 52 plasma renin activity 52 idiopathic myelofibrosis 52 noninferiority 52 colorectal liver metastases 52 cardiac dysfunction 52 IV NSCLC 52 sentinel lymph node biopsy 52 symptomatic VTE 52 IPAH 52 CTEPH 52 meta regression 52 severe sepsis 52 hepatic lesions 52 Cypher Stent 52 chest radiographs 52 Lymph node 52 PFO migraine 52 diagnose coronary artery 52 prostate carcinogenesis 52 bladder carcinoma 52 cardiac perfusion 52 cystatin C 52 pharmacologic treatments 52 ECG gated 52 radical cystectomy 52 advanced neoplasia 52 NATRECOR ® 52 bronchoscopic 52 nonfatal myocardial infarction MI 52 Echocardiographic 52 inotropic 52 FFR measurements 52 randomizing patients 52 deCODE ProstateCancer TM 52 GISSI HF 52 immunotherapeutic approaches 52 therapeutic interventions 52 BFPET 52 CYP#C# genotype 52 inflammatory biomarkers 52 stenoses 52 electrocardiographic 52 mediastinoscopy 52 Zemiva 52 taxane therapy 52 FISH fluorescence 52 neovascular diseases 52 radical prostatectomy RP 52 Anticoagulation 52 ReN# 52 TACE 52 PSA velocity 52 familial hypercholesterolemia 52 radiotherapy RT 52 venous thromboembolic disease 52 histologies 52 molecular assays 52 MarginProbe 52 pre operatively 52 subclinical disease 52 bi ventricular pacing 52 Diabetes Risk Score 52 coronary arteriography 52 CSF biomarkers 52 BioMAP 52 BRIM2 52 VeraTag assays 52 Garcia Manero 52 antioxidant supplementation 52 clinicopathological 52 surrogate markers 52 BRCA mutation carriers 52 transesophageal 52 Acute Coronary Syndromes 52 CK MB 52 MitraClip device 52 ASCUS 52 progressive dyspnea 52 transplantation HCT 52 palliative radiotherapy 52 antimicrobial prophylaxis 52 breast carcinoma 52 multidetector row 52 hypervascular tumors 52 stenting 52 transthoracic 52 MADIT CRT 52 renal biopsy 52 MDCT 52 Zevalin consolidation 52 treating cancerous tumors 52 Reynolds Risk Score 52 hepatocellular carcinoma 52 prospective multicenter study 52 chemotherapeutic regimens 52 EuroSCORE 52 Prognostic factors 52 acute myocardial infarction 52 carotid atherosclerosis 52 MDCT angiography 52 methylation markers 52 PRIMO CABG2 52 sustained virological response 52 artery stenosis 52 MelaFind R 52 Hp2 2 52 antihypertensive therapy 52 Liver transplantation 52 RE LY ® 52 ELACYT 52 cytogenic 52 endoscopic ultrasound 52 Erythropoietic therapies may 52 baseline LDH 52 PAOD 52 Colorectal cancer screening 52 unfavorable cytogenetics 52 duplex ultrasonography 52 pharmacogenetic testing 52 nonmetastatic 52 Cardiovascular Risk 52 empiric therapy 52 glomerular filtration 52 PNH patients 52 multicentre randomized 52 everolimus eluting stent 52 extensive metabolizers 52 Hyperlipidemia 52 HRCT 52 flexible sigmoidoscopy 52 mTOR inhibitors 52 Ischemic 52 thromboembolic complications 52 WavSTAT 52 K ras mutations 52 Preoperative 52 hemodynamically significant 52 lung fibrosis 52 colorectal cancer CRC 52 Prognostic Value 52 R0 resection 52 hemoglobin A1c levels 52 Multivariate logistic regression 52 renoprotective 52 macrovascular events 52 preserved ejection fraction 52 predictive 52 Factor VIIa 52 STEMI patients 52 individualize therapy 52 ATACAND 52 acute myocardial infarctions 52 metabolomic profiling 52 pathophysiology 52 Ovary removal 52 Ceflatonin 52 neurocognitive function 52 stage IIIB 52 reinfarction 52 macrovascular disease 52 axillary lymph node 52 Randomized controlled 52 pharmacodynamics PD 52 TNM staging 52 adenoma recurrence 52 Abciximab 52 sonographic diagnosis 52 troponin T 52 diabetes hyperlipidemia 52 gastrointestinal malignancies 52 hemodynamics 52 kidney allograft 52 PI3K/mTOR 52 eprotirome 52 sorafenib Nexavar 52 companion diagnostics 52 Predictive modeling 52 CA9 SCAN 52 invasive diagnostic 52 GnRH agonists 52 transurethral resection 52 myelofibrosis polycythemia vera 52 catheter ablations 52 curative therapies 52 recurrent ischemia 52 renal scarring 52 prognostic factors 52 parathyroidectomy 52 hypercholesterolemia 52 serum PSA 52 contrast induced nephropathy 52 hemorrhagic complications 52 clopidogrel pretreatment 52 Renal Cell Carcinoma RCC 52 HER2 positive metastatic breast 52 regorafenib 52 Endothelial dysfunction 52 PREVU x 52 cardiac PET 52 nodal dissection 52 T2D 52 NAVISTAR R 52 platelet activation 52 HNSCC 52 coronary anatomy 52 lowering LDL cholesterol 52 metabolic parameters 52 CRT ICD 52 cTnI 52 co morbidities 52 FDG PET scans 52 resectable 52 cardiac troponin T 52 valve implantation 52 acting insulin analogues 52 atherothrombotic 52 oral anticoagulants 52 phase IIa clinical 52 ADAGIO study 52 radionuclide imaging 52 miRview ® 52 PK PD modeling 52 oral Xeloda 52 heparin induced thrombocytopenia 52 Subgroup analysis 52 chemotherapeutic regimen 52 secondary hyperparathyroidism 52 invasive bladder 52 quantitate 52 myocardial infarctions 51 antiviral therapy 51 transesophageal echocardiography 51 colorectal cancer liver metastases 51 antithrombotics 51 undergoing CABG 51 treating peripheral arterial 51 IL#B 51 Left ventricular hypertrophy 51 Randomized Evaluation 51 percutaneous cryoablation 51 ablative therapy 51 genotypic resistance 51 noninvasive ventilation 51 gastrointestinal GI cancers 51 Routine screening 51 ARB telmisartan 51 nocturnal hemodialysis 51 Pseudomonas aeruginosa infections 51 EEG abnormalities 51 Patient Registry 51 carotid ultrasound 51 LQTS 51 FDG uptake 51 pharmacologic approaches 51 Randomized trials 51 tolerability pharmacokinetics 51 anti JCV antibodies 51 VerifyNow 51 resectable pancreatic cancer 51 Biomarker 51 differential diagnosis 51 neovascularisation 51 procalcitonin 51 Reverse Cholesterol Transport 51 Cardiac resynchronization therapy 51 ConclusionThis 51 thrombolytics 51 atherosclerotic vascular disease 51 perfusion abnormalities 51 EMPOWER TM 51 Aureon 51 myocardial perfusion imaging 51 myocardial infarction 51 FFR guided 51 ENDEAVOR clinical 51 pharmacological therapies 51 albuminuria 51 palliation 51 RECIST Response Evaluation Criteria 51 STEP BD 51 Estrogen Receptor 51 glycemic variability 51 IRX 2 51 Androgen deprivation therapy 51 ACCORD Lipid 51 PSA nadir 51 Cardiac Marker 51 Oncotype DX Recurrence Score 51 APOE genotype 51 Hsp# inhibition 51 Vascugel ® 51 nonalcoholic steatohepatitis 51 defibrillator implantation 51 cardiac troponin 51 NYHA 51 mammographic density 51 Azedra 51 radical nephrectomy 51 liver resection 51 thickness IMT 51 morbidity mortality 51 Sorafenib 51 STEMI 51 CCX# 51 recombinant tissue plasminogen 51 Neoadjuvant 51 Noninvasive 51 cTnT 51 sDNA 51 CT angiography CTA 51 p# inhibitor 51 ICD implantations 51 ENGAGE AF TIMI 51 Meta analyzes 51 thrombolytic agents 51 SLNB 51 AT1R 51 SCr 51 myocardial necrosis

Back to home page